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We would like to thank Dr. Fleisher for taking the time to review and respond to our article. 
As we carefully pointed out in our article, human papillomavirus (HPV)-associated 
oropharyngeal cancers commonly involve the base of the tongue and tonsils, and rarely 
occur in the oral cavity. We agree with Dr. Glick and Dr. Newell Johnson in their August 
2011 guest editorial1 when they say, “Precision is needed about the site of origin of these 
cancers, as lesions at different anatomical locations can have different etiologies and 
different outcomes. To follow and compare epidemiologic studies, there needs to be 
agreement regarding terminology ….”
One of the major issues Dr. Fleisher poses involves communicating with our patients about 
methods to prevent oral HPV infection and HPV-associated oropharyngeal cancers. Patients 
should understand that HPV vaccines are effective in preventing certain HPV infections and 
cancers,2,3 but their effectiveness in preventing oral HPV infection or oropharyngeal cancer 
is unknown. Because the HPV types targeted by the vaccines also are the main types 
responsible for oropharyngeal cancer, both of the available HPV vaccines might reduce 
disease burden. However, the impact of HPV vaccines on these cancers would not be 
apparent for many years.
Tobacco and alcohol use may increase the risk for some HPV-associated oropharyngeal 
cancers in addition to non-HPV-associated head and neck cancers.4 Tobacco-use prevention 
and cessation programs have been shown to be effective in reducing the number of tobacco 
users.5 As we noted in our article, dental health care personnel should ask patients about 
their tobacco and alcohol use, inform users about associated risks, encourage tobacco-use 
cessation and provide appropriate counseling.
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Some studies have shown that oral HPV infection is associated with oral sex or other sexual 
behaviors, while other studies have not.6,7 In addition, important questions remain 
unanswered about oral HPV infection and its link to oropharyngeal cancers. For example, 
what cofactors contribute to oral HPV infection’s leading to cancer? What is the persistence 
and clearance of infection in the oral cavity, and does persistent infection lead to cancer? 
What is the latency period between infection and carcinogenesis? Until we have more 
information on the natural history of these cancers, dental personnel should continue to 
promote proven risk reduction strategies such as tobacco-use cessation and limiting alcohol 
use.
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